Relapsing-remitting multiple sclerosis (RRMS)
Clinical trials for Relapsing-remitting multiple sclerosis (RRMS) explained in plain language.
Never miss a new study
Get alerted when new Relapsing-remitting multiple sclerosis (RRMS) trials appear
Sign up with your email to follow new studies for Relapsing-remitting multiple sclerosis (RRMS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a new oral drug quiet the brain lesions of multiple sclerosis?
Disease control Recruiting nowThis trial is testing an experimental oral drug called rocbrutinib (LP-168) in people with relapsing-remitting multiple sclerosis (RRMS) who have a specific type of brain lesion called paramagnetic rim lesions. The study compares rocbrutinib to an existing treatment, dimethyl fum…
Matched conditions: RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
Phase 2 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
MS breakthrough? trial tests if older patients can ditch heavy drugs
Disease control Recruiting nowThis study looks at whether people with relapsing-remitting multiple sclerosis (RRMS) who are over 40 and have been stable on strong anti-CD20 drugs for at least 3 years can safely switch to milder treatments. The goal is to see if this de-escalation approach prevents disease act…
Matched conditions: RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
Phase 3 • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a gut bacteria byproduct tame MS?
Disease control Recruiting nowThis study tests whether a daily supplement of indole-3-propionic acid (IPA), a substance naturally made by gut bacteria, can help people with relapsing-remitting multiple sclerosis (RRMS). Over 27 months, 220 adults will take either IPA or a placebo. The main goal is to see if I…
Matched conditions: RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
Sponsor: Glostrup University Hospital, Copenhagen • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New MS drug trial aims to reduce brain lesions and relapses
Disease control Recruiting nowThis study tests a new medicine called BCD-281 in people with relapsing-remitting multiple sclerosis (RRMS). The goal is to see if it reduces brain lesions and relapse rates better than the current standard drug. About 292 adults aged 18-55 with mild to moderate disability are be…
Matched conditions: RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
Phase 3 • Sponsor: Biocad • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Eye tracking could revolutionize MS monitoring
Knowledge-focused Recruiting nowThis study looks at whether a new eye-tracking device can help doctors see how well multiple sclerosis (MS) treatment is working. About 224 Canadian adults with relapsing-remitting MS will use the device during routine care. The goal is to find out if eye movement changes can rep…
Matched conditions: RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC